8 results match your criteria: "Northwestern Medicine Cancer Center Warrenville and Northwestern Medicine Proton Center[Affiliation]"
Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001.
Int J Radiat Oncol Biol Phys
November 2023
Columbia University, Vagelos Colleg of Physicians and Surgeons, New York, New York.
Article Synopsis
- * The trial involved 518 adults, with HA-WBRT + memantine resulting in less cognitive decline and lower reported symptom burdens at 6 and 12 months compared to standard treatment.
- * Although HA-WBRT + memantine improved cognitive outcomes and symptom reporting, both treatment groups had similar overall survival rates and side effects.
Novel unconventional radiotherapy techniques: Current status and future perspectives - Report from the 2nd international radiation oncology online seminar.
Clin Transl Radiat Oncol
May 2023
Department of Radiation Oncology, University of Texas, Southwestern Medical Center, Inwood Road Dallas, TX 2280, United States.
•Improvement of therapeutic ratio by novel unconventional radiotherapy approaches.•Immunomodulation using high-dose spatially fractionated radiotherapy.•Boosting radiation anti-tumor effects by adding an immune-mediated cell killing.
View Article and Find Full Text PDFRapidPlan hippocampal sparing whole brain model version 2-how far can we reduce the dose?
Med Dosim
August 2022
Varian Medical Systems Inc, Palo Alto, CA; Allegheny Health Network Cancer Institute, Pittsburgh, PA. Electronic address:
Whole-brain radiotherapy has been the standard palliative treatment for patients with brain metastases due to its effectiveness, availability, and ease of administration. Recent clinical trials have shown that limiting radiation dose to the hippocampus is associated with decreased cognitive toxicity. In this study, we updated an existing Knowledge Based Planning model to further reduce dose to the hippocampus and improve other dosimetric plan quality characteristics.
View Article and Find Full Text PDFRadiotherapy intensification for glioblastoma: enhancing the backbone of treatment.
Chin Clin Oncol
August 2021
Brain & Spine Tumor Center, Northwestern Medicine Cancer Center Warrenville and Northwestern Medicine Proton Center, Warrenville, IL, USA.
Given the impact of radiotherapy on survival outcomes for patients with glioblastoma (GBM), intensification of radiotherapy through dose-escalation and/or dose-per-fraction escalation has been an important area of ongoing investigation. Prior to the introduction of temozolomide, radiotherapy intensification beyond 60-Gy conventionally fractionated radiotherapy did not yield a survival benefit. With the emergence of temozolomide and its radio-sensitizing properties, as well as greater understanding of the patterns of first progression after 60-Gy radiotherapy, hypotheses regarding the impact of radiotherapy intensification have arisen.
View Article and Find Full Text PDFHippocampal Avoidance Prophylactic Cranial Irradiation: A New Standard of Care?
J Clin Oncol
October 2021
Department of Radiation Oncology, Northwestern Medicine Cancer Center Warrenville and Northwestern Medicine Proton Center, Warrenville, IL.
Missing Data in Clinical Studies.
Int J Radiat Oncol Biol Phys
August 2021
NRG Oncology Statistical and Data Management Center, American College of Radiology, Philadelphia, Pennsylvania.
Reply to S.G. Chun et al, A. Levy et al, and N. Andratschke et al.
J Clin Oncol
October 2020
Vinai Gondi, MD, Northwestern Medicine Cancer Center Warrenville and Northwestern Medicine Proton Center, Warrenville, IL; and Paul D. Brown, MD, Mayo Clinic, Rochester, MN.
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.
J Clin Oncol
April 2020
Vanderbilt University Medical Center, Ingram Cancer Center, Nashville, TN.
Purpose: Radiation dose to the neuroregenerative zone of the hippocampus has been found to be associated with cognitive toxicity. Hippocampal avoidance (HA) using intensity-modulated radiotherapy during whole-brain radiotherapy (WBRT) is hypothesized to preserve cognition.
Methods: This phase III trial enrolled adult patients with brain metastases to HA-WBRT plus memantine or WBRT plus memantine.